Partner Demonstrates Significant OS Benefit in First-Line BTC Study
Ivonescimab plus chemotherapy showed statistically significant overall survival superior to Durvalumab plus chemo in the advanced biliary tract cancer Phase III HARMONi-GI1 trial, a significant early-stage development for Summit's partner Akeso.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day